Nabla Bio Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $70M

  • Investors
  • 15

Nabla Bio General Information

Description

Developer of wet-lab technologies designed for the rational design of developable, selective, and functional drugs. The company offers integrated AI-driven modeling, high-throughput multiplex screening, and wet-lab validation, enabling pharmaceutical companies to create drugs against previously undruggable targets with enhanced precision and efficacy.

Contact Information

Website
www.nabla.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Riverside Technology Center
  • 840 Memorial Drive
  • Cambridge, MA 02139
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Riverside Technology Center
  • 840 Memorial Drive
  • Cambridge, MA 02139
  • United States

Nabla Bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nabla Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B) 15-May-2026 $70M Completed Generating Revenue
6. Early Stage VC (Series A) 14-May-2024 Completed Generating Revenue
5. Seed Round 20-Feb-2022 Completed Generating Revenue
4. Accelerator/Incubator 01-Sep-2021 Completed Generating Revenue
3. Grant 01-Jan-2021 Completed Generating Revenue
2. Accelerator/Incubator Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Nabla Bio’s complete valuation and funding history, request access »

Nabla Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
Seed-4
Seed-3
Seed-2
Seed-1 307,138 $0.000100 8% $0.49 $0.49 1x $0.49 2.92%
Seed 1,657,301 $0.000100 8% $6.07 $6.07 1x $6.07 15.75%
To view Nabla Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Nabla Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of wet-lab technologies designed for the rational design of developable, selective, and functional drugs. The
Drug Discovery
Cambridge, MA
22 As of 2026

San Mateo, CA
 

Schlieren, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nabla Bio Competitors (36)

One of Nabla Bio’s 36 competitors is BigHat Biosciences, a Venture Capital-Backed company based in San Mateo, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BigHat Biosciences Venture Capital-Backed San Mateo, CA
InterAx Venture Capital-Backed Schlieren, Switzerland
AbCellera Biologics Formerly VC-backed Vancouver, Canada
Sygnature Discovery Private Equity-Backed Nottingham, United Kingdom
BPS Bioscience Corporation San Diego, CA
You’re viewing 5 of 36 competitors. Get the full list »

Nabla Bio Patents

Nabla Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12040050-B1 Systems and methods for rational protein engineering with deep representation learning Active 06-Mar-2019

Nabla Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nabla Bio Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
BluePointe Ventures Venture Capital Minority
Braidwell Hedge Fund Minority
GRIDS Capital Venture Capital Minority
Radical Ventures Venture Capital Minority
Boom Capital Ventures Venture Capital Minority
You’re viewing 5 of 15 investors. Get the full list »

Nabla Bio FAQs

  • When was Nabla Bio founded?

    Nabla Bio was founded in 2020.

  • Where is Nabla Bio headquartered?

    Nabla Bio is headquartered in Cambridge, MA.

  • What is the size of Nabla Bio?

    Nabla Bio has 22 total employees.

  • What industry is Nabla Bio in?

    Nabla Bio’s primary industry is Drug Discovery.

  • Is Nabla Bio a private or public company?

    Nabla Bio is a Private company.

  • What is the current valuation of Nabla Bio?

    The current valuation of Nabla Bio is .

  • What is Nabla Bio’s current revenue?

    The current revenue for Nabla Bio is .

  • How much funding has Nabla Bio raised over time?

    Nabla Bio has raised $107M.

  • Who are Nabla Bio’s investors?

    BluePointe Ventures, Braidwell, GRIDS Capital, Radical Ventures, and Boom Capital Ventures are 5 of 15 investors who have invested in Nabla Bio.

  • Who are Nabla Bio’s competitors?

    BigHat Biosciences, InterAx, AbCellera Biologics, Sygnature Discovery, and BPS Bioscience are some of the 36 competitors of Nabla Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process